A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort
Authors' conclusion
In our real-world prospective RHEUMTAP cohort study on the outcomes of different medication tapering groups in well-controlled RA, patients who tapered or stopped bDMARDs/tsDMARDs with or without background therapy were more likely to experience a flare than patients that did not taper any medications and those that tapered only csDMARDs.
Study context
- Population
- Patients with RA in sustained remission or low disease activity on stable bDMARD/tsDMARDs +/- csDMARDs for at least 6 months52 underwent taper
- Participants
- 131 patients
- Exposure
- Medication tapering/stopping vs no taper
- Any tapern = 52
- Outcome
- Flare
- Follow-up
- 2 years
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
Any taper
15
events
No taper
2
events
Hazard ratio (95% CI)P value
Any tapervs No taper
10.43(2.98–36.53)
P = 0.0002Only bDMARD/tsDMARD tapervs No taper
31.43(6.35–155.55)
P < 0.0001Both csDMARD and bDMARD/tsDMARD tapervs No taper
18.45(2.55–133.37)
P = 0.0039Only csDMARD tapervs Only bDMARD/tsDMARD taper
0.09(0.01–0.69)
P = 0.0213Observational data: associations, not effects.
Original publication
A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort. Rheumatology (Oxford). Published 19 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →